ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS

• Our Unified Platform Serves As eSource For COVID Treatment Trial

  Signant Biotech optimized technology for an emerging biopharmaceutical's Phase 2 COVID treatment trial in critically ill patients, minimizing paper data risks and streamlining consent and data management across multiple sites and solutions.

• Simplifying The Vineland-3: Assisting Raters, Reducing Burden, And Improving Data Quality

  Electronic versions of both Vineland-II and Vineland-3 have been developed with features to improve data accuracy and consistency such as built-in prompts, item-specific scoring guidance, and automated calculations.

• The Intelligent Teammate: Agentic AI As A Catalyst For Clinical Innovation

  Agentic AI cuts variability, speeds clinical workflows, and strengthens compliance. It boosts efficiency and supports teams as research demands grow. Explore the full article for insights.

• RTSM: Randomization And Cohort Management, IP Inventory Management

  Signant’s SmartSignals® RTSM solution helped an innovative biopharmaceutical company secure an FDA Orphan Drug designation for its cardiomyopathy drug.

• eSource vs. EDC: Reimagining Your Clinical Trials

  Explore how an eSource approach to clinical trial data can reduce site burden, eliminate double data entry, minimize queries, and enhance remote monitoring.

• How Technology Can Empower CAR T-Cell Therapy Clinical Trials

  Explore how innovative technologies are pushing advancements in CAR T-cell therapy, enhancing patient outcomes, and streamlining trial processes.

• Using eConsent Data To Populate Site And Sponsor Data Systems

  A top-10 pharmaceutical company was looking to reduce the amount of administrative burden on their clinical trial sites and themselves. See how we accomplished it, using eConsent.

• Endpoint Reliability And eCOA Solutions Facilitate CNS Trial Success

  A Japan-based pharmaceutical development company utilized Signant's eCOA solutions and knowledge to ensure the reliability of endpoints in their Phase 3 and extended-duration CNS trials.

• Top 10 HEOR Trends Report

  Emerging trends in HEOR reveal how AI, real‑world evidence, value‑based care, digital health, and evolving affordability pressures are reshaping global healthcare.

• Innovation And Architecture That Delivers Simplicity And Customizability

  Whether you're looking for no-code simplicity, low-code adaptability, or fully programmable control, this purpose-built technology platform supports trials of all complexities with ease.